Intra-Cellular Stock Story

ITCI -  USA Stock  

USD 57.88  0.15  0.26%

Intra-Cellular Ther Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 745.38 Million. The current Invested Capital Average is estimated to increase to about 525.9 M, while Net Income Per Employee is projected to decrease to (574 K). One of the important factors of profitable assets selection is to know the future growth potential of an asset before buying its shares. This post will concentrate on Intra-Cellular Ther. We will evaluate if Intra-Cellular Ther shares are reasonably priced going into February. We currently estimate Intra-Cellular Ther as undervalued. The real value is approaching 48.26 per share.
Published over three months ago
View all stories for Intra-Cellular Ther | View All Stories
Will Intra Cellular Ther (NASDAQ:ITCI) fundamental indicators remain fragile in February?
Intra-Cellular Ther investment recommendation module can be used to check and cross-verify current trade recommendations provided by analysts evaluating the entity's potential to grow using all of fundamental, technical, data market data available at the time.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Intra-Cellular Ther income statement, its balance sheet, and the statement of cash flows. Potential Intra-Cellular Ther investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Intra-Cellular Ther investors may use each financial statement separately, they are all related. The changes in Intra-Cellular Ther's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Intra-Cellular Ther's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Intra-Cellular Ther fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Intra-Cellular Ther performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Intra-Cellular Ther shares is the value that is considered the true value of the share. If the intrinsic value of Intra-Cellular is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Intra-Cellular Ther.
Please read more on our fundamental analysis page.

Are Intra-Cellular Ther Earnings Expected to grow?

The future earnings power of Intra-Cellular Ther involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Intra-Cellular Ther factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Intra-Cellular Ther stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Intra-Cellular expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Intra-Cellular Ther, but it might be worth checking our own buy vs. sell analysis

Intra-Cellular Ther Gross Profit

Intra-Cellular Ther Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Intra-Cellular Ther previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Intra-Cellular Ther Gross Profit growth over the last 10 years.
Please check Gross Profit in more details.

Exercise or conversion by Joel Marcus of 14189 shares of Intra-Cellular Ther subject to Rule 16b-3

Legal trades by Intra-Cellular Ther insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Intra-Cellular insider trading alert for exercise of restricted stock units by Joel Marcus, the corporate stakeholder, on 13th of May 2022. This event was filed by Intracellular Therapies I with SEC on 2022-05-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Intra-Cellular Ther valued objectively by the market?

Institutional investors typically avoid acquiring a high percentage of Intra-Cellular Ther stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Intra-Cellular is distributed among investors.

Ownership Allocation

Intra-Cellular Ther has a total of eighty-one million four hundred sixty thousand outstanding shares. The majority of Intra-Cellular Ther outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Intra-Cellular Ther to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Intra-Cellular Ther. Please pay attention to any change in the institutional holdings of Intra-Cellular Ther as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Retail Investors3.36
 2021 2022 (projected)
Interest Expense33.1 K33.97 K
Gross Profit18.83 M20.31 M

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Intra-Cellular Ther has an asset utilization ratio of 13.01 percent. This implies that the company is making $0.13 for each dollar of assets. An increasing asset utilization means that Intra-Cellular Ther is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets
857.3 M
Current Assets857.27 Million96.29
Assets Non Current32.77 Million3.68
Tax Assets244,4150.0275

Will Intra-Cellular Ther current rise continue?

Value At Risk just dropped to -5.41, may hint to upcoming price decrease. Intra-Cellular Ther exhibits very low volatility with skewness of 0.35 and kurtosis of 4.03. However, we advise investors to further study Intra-Cellular Ther technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Intra-Cellular Ther's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Intra-Cellular Ther's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Intra-Cellular Ther Implied Volatility

Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.

Our Conclusion on Intra-Cellular Ther

While some companies under the drug manufacturers—specialty & generic industry are still a bit expensive, Intra-Cellular Ther may offer a potential longer-term growth to stockholders. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Intra-Cellular as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Intra-Cellular Ther.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Intra-Cellular Ther. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to